Pfizer unveils Phase 3 results showing HYMPAVZI significantly reduces bleeding in haemophilia patients with inhibitors

Pfizer has announced Phase 3 data demonstrating that its investigational therapy, HYMPAVZI (marstacimab), delivers significant reductions in bleeding episodes in adults and adolescents living with hemophilia A or B who have developed inhibitors. …